A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Trial To Assess The Efficacy And Safety Of 4-Week Administration Of Multiple Oral Doses Of PF-04620110 In Type 2 Diabetes Mellitus Subjects With Insufficient Glycemic Control On Metformin
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
Chula Vista, California, Estados Unidos, 91911
- Pfizer Investigational Site
-
-
Florida
-
DeLand, Florida, Estados Unidos, 32720
- Pfizer Investigational Site
-
Miami Gardens, Florida, Estados Unidos, 33169
- Pfizer Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male and/or female subjects between the ages of 18 and 60 years;
- Body Mass Index (BMI) of >25.0 kg/m2 and <40 kg/m2;
- Subjects must have a historical diagnosis of T2DM in accordance with the ADA guidelines;
- Subjects who have been on well-tolerated and stable doses of metformin
Exclusion Criteria:
- Recent evidence (6 months prior to screening) or history of unstable major organ disease;
- Diagnosis of Type 1 diabetes mellitus;
- Current medical history of myocardial infarction, unstable angina, or history of stroke (including TIA) within 6 months prior to Screening;
- Treatment with thiazolidinediones (TZDs), or subcutaneously administered antidiabetic agents;
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador de Placebo: placebo
|
Matching placebo giving for 4 weeks
|
|
Experimental: PF-04620110
|
5 mg of PF-04620110 given once daily
2.5 mg of PF-04620110 given twice daily
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Post-Prandial Glucose Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28
Prazo: Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT.
Linear trapezoidal method was used to compute AUC.
|
Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in 24-Hour Average Plasma Glucose (APG) Post-Dose at Day 28
Prazo: Baseline (Day -1); 24 hours post-dose on Day 28
|
APG= AUC (0-24)/24.
AUC (0-24) was computed using Linear trapezoidal method.
|
Baseline (Day -1); 24 hours post-dose on Day 28
|
|
Change From Baseline in Post-Prandial Insulin Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28
Prazo: Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
Change from baseline in post-prandial plasma insulin AUC under the plasma insulin concentration versus time curve as determined by standardized MMTT.
Linear trapezoidal method was used to compute AUC.
|
Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
|
Change From Baseline in Post-Prandial C-Peptide Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28
Prazo: Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
Change from baseline in post-prandial area under the plasma C-peptide concentration time curve as determined by standardized MMTT.
Linear trapezoidal method was used to compute AUC.
|
Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
|
Change From Baseline in Post-Prandial Net Triglyceride Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) After a Mixed Meal Tolerance Test (MMTT) at Day 28
Prazo: Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
Change from baseline in post-prandial area under the plasma net triglyceride concentration time curve as determined by standardized MMTT.
Linear trapezoidal method was used to compute AUC.
|
Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
|
Change From Baseline in Total Amide Glucagon Like Peptide-1 (GLP-1) and Active Glucagon Like Peptide-1 (GLP-1) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28
Prazo: Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
Change from baseline in total amide GLP-1 and active GLP-1 area under the plasma concentration time curve was computed by Linear trapezoidal method.
|
Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
|
Change From Baseline in Gastric Inhibitory Peptide (GIP) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28
Prazo: Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
Change from baseline in GIP area under the plasma concentration time curve was computed by Linear trapezoidal method.
|
Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
|
Change From Baseline in Peptide YY (PYY) Area Under the Concentration-Time Curve From Time 2 to 6 Hours (AUC 2-6) at Day 28
Prazo: Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
Change from baseline in PYY area under the plasma concentration time curve was computed by Linear trapezoidal method.
|
Baseline (Day -1); 2 to 6 hours post-dose on Day 28
|
|
Change From Baseline in Fasting Glucose at Day 28
Prazo: 0 hour (pre-dose) on Day -1, Day 28
|
0 hour (pre-dose) on Day -1, Day 28
|
|
|
Change From Baseline in Fasting Insulin at Day 28
Prazo: 0 hour (pre-dose) on Day -1, Day 28
|
0 hour (pre-dose) on Day -1, Day 28
|
|
|
Change From Baseline in Fasting Net Triglycerides at Day 28
Prazo: 0 hour (pre-dose) on Day -1, Day 28
|
0 hour (pre-dose) on Day -1, Day 28
|
|
|
Change From Baseline in Post-Lunch Glucose Excursions Area Under the Concentration-Time Curve From Time 6 to 10 Hours (AUC 6-10) Post-dose at Day 28
Prazo: Baseline (Day -1); 6 to 10 hours post-dose on Day 28
|
Change from baseline in post-lunch glucose excursion under the plasma concentration time curve was computed by Linear trapezoidal method.
|
Baseline (Day -1); 6 to 10 hours post-dose on Day 28
|
|
Change From Baseline in Post-Dinner Glucose Excursions Area Under the Concentration-Time Curve From Time 12 to 16 Hours (AUC 12-16) Post-dose at Day 28
Prazo: Baseline (Day -1); 12 to 16 hours post-dose on Day 28
|
Change from baseline in post-dinner glucose excursion under the plasma concentration time curve was computed by Linear trapezoidal method.
|
Baseline (Day -1); 12 to 16 hours post-dose on Day 28
|
|
Maximum Observed Plasma Concentration (Cmax) of PF-04620110
Prazo: 24 hours post-morning dose on Day 28
|
24 hours post-morning dose on Day 28
|
|
|
Minimum Observed Plasma Trough Concentration (Cmin) of PF-04620110
Prazo: 24 hours post-morning dose on Day 28
|
24 hours post-morning dose on Day 28
|
|
|
Time to Cmax (Tmax) of PF-04620110
Prazo: 24 hours post-morning dose on Day 28
|
24 hours post-morning dose on Day 28
|
|
|
Area Under the Concentration-Time Curve AUC (0-24) of PF-04620110
Prazo: 24 hours post-morning dose on Day 28
|
Area under the plasma concentration-time curve from time 0 (pre-dose) to 24 hours. AUC (0-24) was computed using the linear trapezoidal method. |
24 hours post-morning dose on Day 28
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- B0961007
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .